Pisa, Italy
Pisa, Italy

The University of Pisa , is an Italian public research university located in Pisa, Italy. It was founded in 1343 by an edict of Pope Clement VI. It is the 19th oldest extant university in the world and the 10th oldest in Italy. The prestigious university is ranked between first and third places nationally, in the top 30 in Europe and the top 300 in the world. It houses the Orto botanico di Pisa, Europe's oldest academic botanical garden, which was founded in 1544.The University of Pisa is part of the Pisa University System, which includes the Scuola Normale Superiore and the Sant'Anna School of Advanced Studies. The university has about 57,000 students .In the fields of philology and cultural studies, the University of Pisa is a leading member of ICoN, an inter-university consortium of 21 Italian universities supported by the Ministry of Education, Universities and Research, as well as a member of the European University Association, the Partnership of a European Group of Aeronautics and Space Universities network and the Cineca consortium. It's the only university in Italy which has become a member of the prestigious Universities Research Association.Among its notable graduates there are several national and foreign political leaders including two Italian presidents, five Popes, five Italian prime ministers and three Nobel Laureates as students, faculty or staff affiliates.Pisa has an intense athletic rivalry with the University of Pavia, which traditionally culminates in the Pisa-Pavia Regatta , the oldest competition of this kind in Italy, and second in Europe only to the Oxford Cambridge boat race.In 2013, the University of Pisa finished with La Sapienza University of Rome in first place among the Italian universities, according to the Academic Ranking of World Universities. Wikipedia.


Time filter

Source Type

Patent
University of Pisa and Laboratori Archa S.r.l. | Date: 2017-05-24

The present invention refers to the use as tanning agents for animal pelts of known furan derivatives, which are not toxic and biodegradable, and to a tanning process economically sustainable and comprising a phase of treatment of the pelts directly with aqueous solutions comprising said furan derivatives, obtained by hydrolysis of a lignocellulosic biomass.


Patent
University of Pisa | Date: 2017-07-12

The present invention refers to thermoplastic polymer compositions, highly biodegradable, based on polycaprolactone and a proteic hydrolysate material, that are useful for the quick prototyping with 3D printers and for the manufacture of semi-finished products in the form of filaments, pellets and thin films by hot extrusion.


HarmonicSS vision is to create an International Network and Alliance of partners and cohorts, entrusted with the mission of addressing the unmet needs in primary Sjogren Syndrome; working together to create and maintain a platform with open standards and tools, designed to enable secure storage, governance, analytics, access control and controlled sharing of information at multiple levels along with methods to make results of analyses and outcomes comparable across centers and sustainable through Rheumatology associations. The overall idea of the HarmonicSS project is to bring together the largest well characterized regional, national and international longitudinal cohorts of patients with Primary Sjgrens Syndrome (pSS) including those participating in clinical trials, and after taking into consideration the ethical, legal, privacy and IPR issues for sharing data from different countries, to semantically interlink and harmonize them into an integrative pSS cohort structure on the cloud. Upon this harmonized cohort, services for big data mining, governance and visual analytics will be integrated, to address the identified clinical and health policy pSS unmet needs. In addition, tools for specific diagnostic procedures (e.g. ultrasonography image segmentation), patient selection for clinical trials and training will be also provided. The users of the HarmonicSS platform are researchers (basic/translational), clinicians, health policy makers and pharma companies. pSS is relevant not only due to its clinical impact but also as one of the few model diseases to link autoimmunity, cancer development (lymphoproliferation) and the pathogenetic role of infection. Thus, the study of pSS can facilitate research in many areas of medicine; for this reason, the possibility for sustainability and expandability of the platform is enhanced. Moreover, pSS has a significant impact on the healthcare systems, similar to that of rheumatoid arthritis.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: LCE-17-2015 | Award Amount: 9.63M | Year: 2016

The share of renewable energy is growing rapidly driven by the objective to reduce greenhouse gas emissions. The amount of electric power which can be supplied to the grid depends on the time of the day and weather conditions. A conventional fleet of thermal power plants is required to compensate for these fluctuations before large scale energy storage technologies will be mature and economically viable. All power market projections expect this to be the case for the next 50 years at least. For a strong expansion of renewables, this fleet has to operate flexibly at competitive cost. Current power plants cannot fill this role immediately without impeding their efficiency and engine lifetime through increased wear and damage induced by the higher number of (shorter) operating/loading cycles. New technologies need to be introduced to balance demand peaks with renewable output fluctuations at minimal fuel consumption and emissions without negative effects on cycling operation. The FLEXTURBINE partners have developed a medium to long term technology roadmap addressing future and existing power plants. The FLEXTURBINE project presented hereafter is the first step in such technology roadmap and consists of: (1) new solutions for extended operating ranges to predict and control flutter, (2) improved sealing and bearing designs to increase turbine lifetime and efficiency by reducing degradation/damages, and (3) an improved lifecycle management through better control and prediction of critical parts to improve competitive costs by more flexible service intervals and planned downtime, and by reducing unplanned outages. In all areas, individual technologies will be developed from TRL 3 to TRL 4-6. FLEXTURBINE brings together the main European turbine manufacturers, renowned research institutes and universities. It involves plant and transmission system operators to include user feedback and to prepare the take-up of the FLEXTURBINE technologies in power plants world-wide.


Grant
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016

This project is the second in the series of EC-financed parts of the Graphene Flagship. The Graphene Flagship is a 10 year research and innovation endeavour with a total project cost of 1,000,000,000 euros, funded jointly by the European Commission and member states and associated countries. The first part of the Flagship was a 30-month Collaborative Project, Coordination and Support Action (CP-CSA) under the 7th framework program (2013-2016), while this and the following parts are implemented as Core Projects under the Horizon 2020 framework. The mission of the Graphene Flagship is to take graphene and related layered materials from a state of raw potential to a point where they can revolutionise multiple industries. This will bring a new dimension to future technology a faster, thinner, stronger, flexible, and broadband revolution. Our program will put Europe firmly at the heart of the process, with a manifold return on the EU investment, both in terms of technological innovation and economic growth. To realise this vision, we have brought together a larger European consortium with about 150 partners in 23 countries. The partners represent academia, research institutes and industries, which work closely together in 15 technical work packages and five supporting work packages covering the entire value chain from materials to components and systems. As time progresses, the centre of gravity of the Flagship moves towards applications, which is reflected in the increasing importance of the higher - system - levels of the value chain. In this first core project the main focus is on components and initial system level tasks. The first core project is divided into 4 divisions, which in turn comprise 3 to 5 work packages on related topics. A fifth, external division acts as a link to the parts of the Flagship that are funded by the member states and associated countries, or by other funding sources. This creates a collaborative framework for the entire Flagship.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-26-2016 | Award Amount: 6.99M | Year: 2017

Today, intralogistic services have to respond quickly to changing market needs, unforeseeable trends and shorter product life cycles. These drivers pose new demands on intralogistic systems to be highly flexible, rock-solid reliable, self-optimising, quickly deployable and safe yet efficient in environments shared with humans. ILIAD will enable the transition to automation of intralogistic services with key stakeholders from the food distribution sector, where these challenges are particularly pressing. We will develop robotic solutions that can integrate with current warehouse facilities, extending the state of the art to achieve self-deploying fleets of heterogeneous robots in multiple-actor systems; life-long self-optimisation; manipulation from a mobile platform; efficient and safe operation in environments shared with humans; and efficient fleet management with formal guarantees. Scientifically, ILIAD pursues ambitious goals for complex cognitive systems in human environments beyond a specific use-case. We will overcome limitations in the state of the art in tracking and analysing humans; quantifying map quality and predicting future states depending on activity patterns inferred from long-term observations; planning of socially normative movements using learned human models; integration of task allocation, coordination and motion planning for heterogeneous robot fleets; and systematically studying human safety in mixed environments, providing a foundation for future safety standards. Our consortium is uniquely placed to tackle these challenges and to maximise exploitation beyond the projects duration. It includes partners with a proven track record in all key research areas, leading technology providers for intralogistics, end users that are leading in their respective markets, and the National Centre for Food Manufacturing at partner UoL, facilitating access to realistic test sites. This mix of partners will ensure a very high impact of the project results.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETOPEN-01-2016-2017 | Award Amount: 3.79M | Year: 2017

Optoelectronic devices typically operate in the weak coupling regime between light and matter, for example in conventional lasers relying on population inversion to achieve optical gain. Recently there has been a surge of interest in quantum systems operating instead in the strong coupling regime, when the coupling strength of the light-matter interaction is so strong that new states cavity polaritons are created, that are partially light, partially material excitation. In semiconductors, exciton-polaritons have been the most widely studied type of strongly coupled system. Recently a new phenomenon has been realized exploiting intersubband transitions. The resulting excitations are called intersubband polaritons, and they have two remarkable properties: (i) a bosonic character that is maintained up to high carrier densities since they are not restricted by the Mott transition limit; (ii) large Rabi splittings. Although the scientific community has explored the basic science of intersubband polaritons, their potential for future and innovative optoelectronic devices has been entirely untapped. The MIR-BOSE project will realize this potential, and demonstrate disruptive optoelectronic devices operating in the strong coupling regime between light and matter. We will demonstrate the first bosonic lasers operating in the mid-IR and THz ranges of the electromagnetic spectrum. Laser action here does not rely on population inversion, so we will achieve temperature independent operation and high powers. We will demonstrate a new concept of inverse-Q-switching leading to the generation of high power pulses in the mid-IR, overcoming severe bottlenecks in current technology. Finally, we will demonstrate non-classical/quantum light sources and devices, generating squeezed states of light in the mid-IR/THz spectral range for quantum optics. These new sources will have a major impact on several technologies and applications, being advantageous compared to current solutions.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.89M | Year: 2017

Personalized health is a European priority and one of the strategic research areas for Horizon 2020. This project advances the state-of-the-art of personal health technologies for affective disorders, estimated to be the highest ranking cause of disease by 2020. It marks a significant shift from the current wearable technologies capturing emotional responses whose understanding usually requires physicians input, to low-cost self-help technologies for visualizing, exploring and regulating emotions. AFFECTIVA integrates the latest Human-Computer Interaction and Biomedical Engineering findings in designing and developing personal health systems for mental health, with the most influential outcomes and models of emotion regulation from Clinical Psychology. The overall aim is to support self-understanding and successful adoption of adaptive emotion regulation strategies in daily life. AFFECTIVA will contribute towards four significant outcomes: (1) wearable systems for capturing emotion regulation, (2) applications for understanding emotions and their regulatory processes, (3) interactive tools for training adaptive emotion regulation strategies, and (4) theoretical contributions to emotion regulation research in real life. AFFECTIVA builds on exceptional European and North American expertise from both academic and private sector to provide personalized health research with a timely and much needed momentum to address the pressing social challenge of emotional wellbeing and health.


Lencioni R.,University of Pisa
Hepatology | Year: 2010

Loco-regional treatments play a key role in the management of hepatocellular carcinoma (HCC). Image-guided tumor ablation is recommended in patients with early-stage HCC when surgical options are precluded. Radiofrequency ablation has shown superior anticancer effects and greater survival benefit with respect to the seminal percutaneous technique, ethanol injection, in meta-analyses of randomized controlled trials, and is currently established as the standard method for local tumor treatment. Novel thermal and nonthermal techniques for tumor ablation - including microwave ablation, irreversible electroporation, and light-activated drug therapy - seem to have potential to overcome the limitations of radiofrequency ablation and warrant further clinical investigation. Transcatheter arterial chemoembolization (TACE) is the standard of care for patients with asymptomatic, noninvasive multinodular tumors at the intermediate stage. The recent introduction of embolic microspheres that have the ability to release the drug in a controlled and sustained fashion has been shown to significantly increase safety and efficacy of TACE with respect to conventional, lipiodol-based regimens. The available data for radioembolization with yttrium-90 suggests that this is a potential new option for patients with HCC, which should be investigated in the setting of randomized controlled trials. Despite the advances and refinements in loco-regional approaches, the long-term survival outcomes of patients managed with interventional techniques are not fully satisfactory, mainly because of the high rates of tumor recurrence. The recent addition of molecular targeted drugs with antiangiogenic and antiproliferative properties to the therapeutic armamentarium for HCC has prompted the design of clinical trials aimed at investigating the synergies between loco-regional and systemic treatments. The outcomes of these trials are eagerly awaited, because they have the potential to revolutionize the treatment of HCC. Copyright © 2010 by the American Association for the Study of Liver Diseases.


Lencioni R.,University of Pisa
Clinical Cancer Research | Year: 2013

The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice. © 2013 AACR.

Loading University of Pisa collaborators
Loading University of Pisa collaborators